Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872555 | 0.86 | ALDH1A1 (0.77) | ALDH1A1EGLN1 | |
| SCHEMBL1759043 | 0.84 | ALDH1A1 (1.00) | ALDH1A1EGLN1 | |
| SCHEMBL11973430 | 0.83 | LMNA (0.56) | ALDH1A1EGLN1 | |
| SCHEMBL13943232 | 0.83 | ALDH1A1 (0.54) | ALDH1A1EGLN1 | |
| SCHEMBL8885906 | 0.83 | ALDH1A1 (0.73) | ALDH1A1EGLN1 | |
| SCHEMBL9139640 | 0.83 | ALDH1A1 (0.97) | ALDH1A1EGLN1 | |
| SCHEMBL2143721 | 0.83 | ALDH1A1 (0.73) | ALDH1A1EGLN1 | |
| SCHEMBL2143864 | 0.83 | ALDH1A1 (0.73) | ALDH1A1EGLN1 | |
| SCHEMBL12647755 | 0.82 | ALDH1A1 (0.67) | ALDH1A1EGLN1 | |
| SCHEMBL12664066 | 0.82 | ALDH1A1 (0.67) | ALDH1A1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | claimed |
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150321997-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20140343020-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20120245130-A1 | Methods of Using Substituted Tetracycline Compounds to Modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8227426-B2 | Chiral complexes of ascorbic acid with natural antioxidant and anti-inflammatory ketones including aloe, citrus, ginger, and mango for skin and hair care | ISLAND KINETICS INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8173624-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120101071-A1 | SubstitutedTetracycline Compounds for the Treatment of Malaria | PARATEK PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088820-B2 | administering tetracycline derivatives as antimalarial agents | PARATEK PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1562608-A2 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | Paratek Pharmaceuticals, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1556007-A2 | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA | Paratek Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040242548-A1 | Substituted tetracycline compounds for the treatment of malaria | PARATEK PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040214800-A1 | for Disorders Treatable by Modulation of RNA (DTMRs) including viral, neurodegenerative and others caused or related to RNA function, structure, amounts and/or activities | PARATEK PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004038001-A2 | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004038000-A2 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-0014079-B1 | SPIRO-QUINOLYLHYDANTOINS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1981-11-18 | — | — | EP | disclosed |
| EP-0014079-A1 | Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof | PFIZER INC. (US) | 1980-08-06 | — | — | EP | disclosed |
| US-4176185-A | ALDOSE REDUCTASE ENZYME INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101071-A1 | SubstitutedTetracycline Compounds for the Treatment of Malaria | TET1, DHFR, TET3 | ALDH1A1 2738/4885EGLN1 1816/4885 |
| US-20120245130-A1 | Methods of Using Substituted Tetracycline Compounds to Modulate RNA | NSUN3, NSUN2, RNMT | ALDH1A1 4467/4885EGLN1 2038/4885 |
| US-20150321997-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | ALDH1A1 4467/4885EGLN1 2038/4885 |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | ALDH1A1 4467/4885EGLN1 2038/4885 |
| US-20040242548-A1 | Substituted tetracycline compounds for the treatment of malaria | TET1, TET3, DHFR | ALDH1A1 3389/4885EGLN1 1544/4885 |
| US-20140343020-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | ALDH1A1 4467/4885EGLN1 2038/4885 |
| US-20040214800-A1 | for Disorders Treatable by Modulation of RNA (DTMRs) including viral, neurodegenerative and others caused or related to RNA function, structure, amounts and/or activities | TARDBP, TRDMT1, NSUN3 | ALDH1A1 4596/4885EGLN1 2775/4885 |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | PSMB1, PLOD3, CUTA | ALDH1A1 330/4885EGLN1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.